Related Experiment Video

Updated: Jun 12, 2026

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

[Osteodystrophy in chronic liver disease]

Pia Eiken1, Atheer Adel Al-Omran2, Frank Vinholt Schiødt3

  • 1Endokrinologisk Afdeling, Københavns Universitetshospital - Bispebjerg Hospital.

Ugeskrift for Laeger
|June 11, 2026
PubMed

Insights

Patients with chronic liver disease (CLD) experiencing fragility fractures should be screened for osteoporosis. Early screening and interventions like calcium, vitamin D, and specific medications can improve bone density.

Area of Science:

  • Hepatology
  • Endocrinology
  • Metabolic Bone Disease

Background:

  • Hepatic osteodystrophy is a metabolic bone disease linked to chronic liver disease (CLD).
  • It commonly presents as osteoporosis and fragility fractures.
  • Early identification and management are crucial for patient outcomes.

Purpose of the Study:

  • To review the current understanding of hepatic osteodystrophy.
  • To highlight the importance of early osteoporosis screening in CLD patients.
  • To discuss effective treatment strategies for bone health in CLD.

Main Methods:

  • Literature review of studies on hepatic osteodystrophy and chronic liver disease.
  • Analysis of clinical manifestations, diagnostic criteria, and treatment options.
  • Synthesis of evidence regarding screening protocols and therapeutic interventions.

Main Results:

  • Patients over 50 with CLD and fragility fractures require earlier osteoporosis screening.
  • Standard treatments include calcium, vitamin D, and lifestyle modifications.
  • Pharmacological agents like bisphosphonates and denosumab have shown efficacy in increasing bone mineral density.

Conclusions:

  • Hepatic osteodystrophy necessitates proactive bone health management in CLD.
  • Screening for osteoporosis should be considered earlier in at-risk CLD populations.
  • A combination of nutritional, lifestyle, and medical interventions can effectively manage bone loss.

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Related Concept Videos

Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...